3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
20
Ovarian Neoplasms
19
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Metastatic Castration-resistant Prostate Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Glioma
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Osteosarcoma
2
Neoplasms
2
Glioblastoma
2
Cholangiocarcinoma
2
Carcinosarcoma
2
Carcinoma, Endometrioid
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Muscle Invasive Bladder Cancer
×
olaparib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled